Reply:
Peter Jepsen, Peter Ott, Per Kragh Andersen, Henrik Toft Sørensen, Hendrik Vilstrup – 30 September 2010
Enteric dysbiosis associated with a mouse model of alcoholic liver disease
Arthur W. Yan, Derrick E. Fouts, Johannes Brandl, Peter Stärkel, Manolito Torralba, Eckart Schott, Hide Tsukamoto, Karen E. Nelson, David A. Brenner, Bernd Schnabl – 30 September 2010 – The translocation of bacteria and bacterial products into the circulation contributes to alcoholic liver disease. Intestinal bacterial overgrowth is common in patients with alcoholic liver disease. The aims of our study were to investigate bacterial translocation, changes in the enteric microbiome, and its regulation by mucosal antimicrobial proteins in alcoholic liver disease.
p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3‐kinase/AKT/hypoxia‐inducible factor‐1α pathways
Jing Fu, Yao Chen, Jie Cao, Tao Luo, You‐Wen Qian, Wen Yang, Yi‐Bin Ren, Bo Su, Guang‐Wen Cao, Yuan Yang, Yi‐Qun Yan, Feng Shen, Meng‐Chao Wu, Gen‐Sheng Feng, Hong‐Yang Wang – 30 September 2010 – The overall survival of patients with hepatocellular carcinoma (HCC) remains poor, and the molecular mechanisms underlying HCC progression and aggressiveness are unclear. Here, we report that increased expression of p28GANK (Gankyrin, PSMD10, or p28) in human HCC predicts poor survival and disease recurrence after surgery.
Meeting Report of the 16th Annual International Congress of the International Liver Transplantation Society
Josh Levitsky, Olaf Guckelberger – 28 September 2010
Reply
Doris Wagner, Daniela Kniepeiss, Florian Iberer, Astrid Fahrleitner‐Pammer, Peter Kornprat, Karlheinz Tscheliessnigg – 28 September 2010
The immunosuppressive pipeline: Meeting unmet needs in liver transplantation
Nazia Selzner, David R. Grant, Itay Shalev, Gary A. Levy – 28 September 2010 – Liver transplantation is now recognized as the treatment of choice for end‐stage liver failure. Its success can be attributed largely to the generation of selective immunosuppressive agents, which have resulted in a dramatic reduction in the incidence of acute rejection and improvements in the short‐ and long‐term outcomes of patients.
The MAP3K TAK1: A chock block to liver cancer formation
Yann Malato, Holger Willenbring – 28 September 2010
The recellularized liver matrix: A novel way of transplantation?
Christer Baeck, Konrad Streetz – 28 September 2010
Tumor necrosis factor α sensitizes primary murine hepatocytes to Fas/CD95‐induced apoptosis in a Bim‐ and Bid‐dependent manner
Kathrin Schmich, Rebekka Schlatter, Nadia Corazza, Karine Sá Ferreira, Michael Ederer, Thomas Brunner, Christoph Borner, Irmgard Merfort – 24 September 2010 – Fas/CD95 is a critical mediator of cell death in many chronic and acute liver diseases and induces apoptosis in primary hepatocytes in vitro. In contrast, the proinflammatory cytokine tumor necrosis factor α (TNFα) fails to provoke cell death in isolated hepatocytes but has been implicated in hepatocyte apoptosis during liver diseases associated with chronic inflammation.
C‐reactive protein impairs hepatic insulin sensitivity and insulin signaling in rats: Role of mitogen‐activated protein kinases
Liang Xi, Changting Xiao, Robert H.J. Bandsma, Mark Naples, Khosrow Adeli, Gary F. Lewis – 24 September 2010 – Plasma C‐reactive protein (CRP) concentration is increased in the metabolic syndrome, which consists of a cluster of cardiovascular disease risk factors, including insulin resistance. It is not known, however, whether CRP is merely a marker of accompanying inflammation or whether it contributes causally to insulin resistance. The objective of this study is to investigate the role that CRP may play in the development of insulin resistance.